GlassScriptPhysician profile
Elham Miraliakbari
NPI 1750849998
$8,809.88
in general payments reported to CMS, 2019-2025
25 companies · $1,941 in 2025
The $1,941 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $962 · 2022: $1,726 · 2023: $1,997 · 2024: $2,185 · 2025: $1,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,119 · Travel and Lodging: $3.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,119.37 |
| Travel and Lodging | $3.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,477.63 | 2022-2025 | |
| Allergan, INC. | $1,295.04 | 2021-2022 | |
| Incyte Corporation | $935.71 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $898.60 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $839.33 | 2021-2025 | |
| Lilly USA, LLC | $712.31 | 2022-2025 | Olumiant, Ebglyss, Taltz |
| Janssen Biotech, INC. | $540.44 | 2022-2025 | Tremfya, Simponi, Remicade |
| Regeneron Healthcare Solutions, INC. | $401.90 | 2021-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $312.98 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $255.72 | 2021-2025 | Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $238.23 | 2022-2025 | |
| Galderma Laboratories, L.P. | $232.15 | 2021-2022 | |
| Amgen INC. | $201.32 | 2022-2024 | Otezla, Enbrel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.44 | 2022-2025 | Jublia, Arazlo, Duobrii |
| Ucb, INC. | $127.50 | 2021-2025 | Bimzelx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $35.96 | 2023 | Valchlor |
| Almirall LLC | $32.66 | 2022 | |
| Dermavant Sciences, INC. | $24.67 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.99 | 2025 | Spevigo |
| Organon LLC | $21.55 | 2025 | Nexplanon |
| Dermira, INC. | $20.99 | 2021 | |
| Ani Pharmaceuticals, INC. | $13.92 | 2025 | Purified Cortrophin Gel |
| Sebela Pharmaceuticals INC. | $13.84 | 2023 | Naftin, Pramosone |
| Journey Medical Corporation | $13.77 | 2022 | |
| Biofrontera INC. | $10.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elham Miraliakbari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.